Literature DB >> 26744525

Skin Cancer Risk Is Modified by KIR/HLA Interactions That Influence the Activation of Natural Killer Immune Cells.

Karin A Vineretsky1, Margaret R Karagas2, Brock C Christensen3, Jacquelyn K Kuriger-Laber4, Ann E Perry5, Craig A Storm5, Heather H Nelson6.   

Abstract

Natural killer (NK)-cell phenotype is partially mediated through binding of killer-cell immunoglobulin-like receptors (KIR) with HLA class I ligands. The KIR gene family is highly polymorphic and not well captured by standard genome-wide association study approaches. Here, we tested the hypothesis that variations in KIR gene content combined with HLA class I ligand status is associated with keratinocyte skin cancers using a population-based study of basal cell carcinoma (BCC) and squamous cell carcinomas (SCC). We conducted an interaction analysis of KIR gene content variation and HLA-B (Bw4 vs. Bw6) and HLA-C (C1 vs. C2). KIR centromeric B haplotype was associated with significant risk of multiple BCC tumors (OR, 2.39; 95% confidence interval, 1.10-5.21), and there was a significant interaction between HLA-C and the activating gene KIR2DS3 for BCC (Pinteraction = 0.005). Furthermore, there was significant interaction between HLA-B and telomeric KIR B haplotype (containing the activating genes KIR3DS1 and KIR2DS1) as well as HLA-B and the activating KIR gene KIR2DS5 (Pinteraction 0.001 and 0.012, respectively). Similar but greatly attenuated associations were observed for SCC. Moreover, previous in vitro models demonstrated that p53 is required for upregulation of NK ligands, and accordingly, we observed there was a strong association between the KIR B haplotype and p53 alteration in BCC tumors, with a higher likelihood that KIR B carriers harbor abnormal p53 (P < 0.004). Taken together, our data suggest that functional interactions between KIR and HLA modify risks of BCC and SCC and that KIR encoded by the B genes provides selective pressure for altered p53 in BCC tumors. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26744525      PMCID: PMC4715977          DOI: 10.1158/0008-5472.CAN-15-0547

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

Review 1.  MHC class I molecules and KIRs in human history, health and survival.

Authors:  Peter Parham
Journal:  Nat Rev Immunol       Date:  2005-03       Impact factor: 53.106

Review 2.  Pathogenesis of nonmelanoma skin cancers in organ transplant recipients.

Authors:  Mohammad Athar; Stephanie B Walsh; Levy Kopelovich; Craig A Elmets
Journal:  Arch Biochem Biophys       Date:  2011-01-11       Impact factor: 4.013

3.  Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection.

Authors:  Antonio López-Vázquez; Luis Rodrigo; Jesus Martínez-Borra; Ramón Pérez; Manuel Rodríguez; Juan L Fdez-Morera; Dolores Fuentes; Sandra Rodríguez-Rodero; Segundo Gonzáez; Carlos López-Larrea
Journal:  J Infect Dis       Date:  2005-05-25       Impact factor: 5.226

4.  Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin.

Authors:  Margaret R Karagas; Heather H Nelson; Peter Sehr; Tim Waterboer; Therese A Stukel; Angeline Andrew; Adele C Green; Jan Nico Bouwes Bavinck; Ann Perry; Steven Spencer; Judy R Rees; Leila A Mott; Michael Pawlita
Journal:  J Natl Cancer Inst       Date:  2006-03-15       Impact factor: 13.506

5.  Ganglioside, adhesion molecule, and HLA antigen expression in basal cell carcinoma lesions.

Authors:  T Kageshita; T Ono; S Hirai; A Yoshii; T Kimura; H Nakakuma; K Horikawa; K Takatsuki; S Ferrone
Journal:  Cancer Res       Date:  1992-06-01       Impact factor: 12.701

Review 6.  Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).

Authors:  Amanda K Purdy; Kerry S Campbell
Journal:  Cancer Biol Ther       Date:  2009-12-28       Impact factor: 4.742

7.  HLA molecules in basal cell carcinoma of the skin.

Authors:  T Cabrera; V Garrido; A Concha; J Martín; J Esquivias; M R Oliva; F Ruiz-Cabello; S Serrano; F Garrido
Journal:  Immunobiology       Date:  1992-09       Impact factor: 3.144

8.  Dramatically reduced surface expression of NK cell receptor KIR2DS3 is attributed to multiple residues throughout the molecule.

Authors:  C J VandenBussche; T J Mulrooney; W R Frazier; S Dakshanamurthy; C K Hurley
Journal:  Genes Immun       Date:  2008-11-13       Impact factor: 2.676

Review 9.  Solar and ultraviolet radiation.

Authors: 
Journal:  IARC Monogr Eval Carcinog Risks Hum       Date:  1992

10.  Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population.

Authors:  M R Karagas; T D Tosteson; J Blum; J S Morris; J A Baron; B Klaue
Journal:  Environ Health Perspect       Date:  1998-08       Impact factor: 9.031

View more
  7 in total

Review 1.  Cutaneous squamous cell cancer (cSCC) risk and the human leukocyte antigen (HLA) system.

Authors:  Pooja Yesantharao; Wei Wang; Nilah M Ioannidis; Shadmehr Demehri; Alice S Whittemore; Maryam M Asgari
Journal:  Hum Immunol       Date:  2017-02-07       Impact factor: 2.850

2.  The Immunogenetics of Non-melanoma Skin Cancer.

Authors:  Sabha Mushtaq
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer.

Authors:  Yayi He; Paul A Bunn; Caicun Zhou; Dan Chan
Journal:  Oncotarget       Date:  2016-12-13

4.  Genotype B of Killer Cell Immunoglobulin-Like Receptor is Related with Gastric Cancer Lesions.

Authors:  Eric G Hernandez; Oswaldo Partida-Rodriguez; Margarita Camorlinga-Ponce; Miriam Nieves-Ramirez; Irma Ramos-Vega; Javier Torres; Martha Perez-Rodriguez
Journal:  Sci Rep       Date:  2018-04-17       Impact factor: 4.379

Review 5.  The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.

Authors:  Haoyu Sun; Cheng Sun
Journal:  Front Immunol       Date:  2019-10-17       Impact factor: 7.561

6.  Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes.

Authors:  Barbara Manzanares-Martin; Arancha Cebrián Aranda; Laura Del Puerto-Nevado; Rafael González; Sonia Solanes; Maria Auxiliadora Gómez-España; Jesús García-Foncillas; Enrique Aranda
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

7.  Natural Killer Cell Recognition and Control of Epithelial Cancers.

Authors:  Marcelo de Souza Fernandez Pereira; David R Carr; Margaret E Gatti-Mays; Mallery R Olsen; Bhuvana A Setty; Kathryn T Shahwan; Dean A Lee
Journal:  Cancer J       Date:  2022 Jul-Aug 01       Impact factor: 2.074

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.